| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/19/2006 | WO2006108226A1 Vaccine delivery system |
| 10/19/2006 | WO2006094134A3 Kim-1 antibodies for treatment of th2-mediated conditions |
| 10/19/2006 | WO2006091693A3 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
| 10/19/2006 | WO2006083689A3 Anti a beta antibody formulation |
| 10/19/2006 | WO2006082398A3 Nucleic acid constructs |
| 10/19/2006 | WO2006066078A3 Fcϝriib-specific antibodies and methods of use thereof |
| 10/19/2006 | WO2006065975B1 Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor |
| 10/19/2006 | WO2006065139A3 Deacylation of lps in gram negative bacteria |
| 10/19/2006 | WO2006030220A9 Compositions monovalent for cd40l binding and methods of use |
| 10/19/2006 | WO2006023791A3 Methods and compositions for treating allergic inflammation |
| 10/19/2006 | WO2005111622A8 Diagnostic assay for trypanosoma cruzi infection |
| 10/19/2006 | WO2005097179A3 Stabilised tat antigen and the use thereof for anti-hiv vaccination |
| 10/19/2006 | WO2005092058A3 Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses |
| 10/19/2006 | WO2005068632A8 EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
| 10/19/2006 | WO2005016132A3 Diagnostics for sars virus |
| 10/19/2006 | WO2004020605A3 Circular nucleic acid vectors, and methods for making and using the same |
| 10/19/2006 | US20060236417 Germinal center-associated nuclear protein (GANP); high affinity antibody; humanizing |
| 10/19/2006 | US20060235209 Use of anti-tissue factor antibodies for treating thromboses |
| 10/19/2006 | US20060235206 Monoclonal antibodies that bind Pseudomona mucoid heteropolysaccharides; used in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis); enhance opsonophagocytic killing of multiple mucoid strains |
| 10/19/2006 | US20060235203 MN gene and protein |
| 10/19/2006 | US20060235201 Enduring T cell response |
| 10/19/2006 | US20060235052 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses |
| 10/19/2006 | US20060234971 Calpains as targets for inhibition of prion propagation |
| 10/19/2006 | US20060234968 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 10/19/2006 | US20060234965 Novel full-length genomic rna of Japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |
| 10/19/2006 | US20060234934 Composition and Method for Selective Cytostasis |
| 10/19/2006 | US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis |
| 10/19/2006 | US20060234917 glycoprotein comprising the extracellular domain of a non-naturally occurring BAFF-R; BAFF (B-cell-activating factor of the TNF family); immunologic, autoimmune diseases, cancers, virus-associated diseases, renal, hypertensive diseases, conditions requiring immunosuppression, inflammation |
| 10/19/2006 | US20060234342 Human DNA topoisomerase I alpha |
| 10/19/2006 | US20060234286 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses |
| 10/19/2006 | US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 10/19/2006 | US20060234240 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f) |
| 10/19/2006 | US20060234227 Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes |
| 10/19/2006 | US20060234213 Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses |
| 10/19/2006 | US20060233857 Degradable elastomeric network |
| 10/19/2006 | US20060233840 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 10/19/2006 | US20060233839 Novel compounds |
| 10/19/2006 | US20060233838 Method for the purification, recovery, and sporulation of cysts and oocysts |
| 10/19/2006 | US20060233837 Vibrio cholerae vaccine candidates, the methods of their constructing and medicinal preparations derived thereof |
| 10/19/2006 | US20060233836 Complex comprising peptide substrate such as synaptosomal associated protein, syntaxin, isoforms, vesicle-associated membrane protein, and motif of soluble NSF (N-ethylmaleimide-sensitive fusion protein) attachment protein receptor, reporter domain comprising red fluorescent protein |
| 10/19/2006 | US20060233835 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 10/19/2006 | US20060233834 Production of poxviruses with adherent or non adherent avian cell lines |
| 10/19/2006 | US20060233833 Novel uses of parapoxvirus preparations |
| 10/19/2006 | US20060233832 Composition for the prophylaxis and treatment of HBV infections and HBV-mediated diseases |
| 10/19/2006 | US20060233831 Novel vaccine formulations |
| 10/19/2006 | US20060233830 Vaccines |
| 10/19/2006 | US20060233829 Regulated attenuation of live vaccines to enhance cross-protective immunogenicity |
| 10/19/2006 | US20060233827 85kDa neisserial antigen |
| 10/19/2006 | US20060233826 Nucleotide sequences coding chlamydial membrane protein for use in generating neutralizing antibody which prevents micoorganismal infection |
| 10/19/2006 | US20060233825 C. perfringens alpha toxoid vaccine |
| 10/19/2006 | US20060233824 Staphylococcal protein specific immunoglobulin for use in prevention and treatment of microorganismal infection |
| 10/19/2006 | US20060233823 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof |
| 10/19/2006 | US20060233822 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 10/19/2006 | US20060233821 Compositions and methods for the inhibition of membrane fusion by paramyxoviruses |
| 10/19/2006 | US20060233820 Inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression; cancers associated with an infection |
| 10/19/2006 | US20060233819 Inhibition of T cell activation by butyrophilin 4 or B7-L1 |
| 10/19/2006 | US20060233818 Organic compounds |
| 10/19/2006 | US20060233817 Peptide-based immunization therapy for treatment of atherosclerosis |
| 10/19/2006 | US20060233816 Use of plant oil-bodies in vaccine delivery systems |
| 10/19/2006 | US20060233815 Agents for protection from neointimal formation in grafts comprising an nfkappab decoy |
| 10/19/2006 | US20060233814 Elimination of heterogeneous or mixed cell population in tumors |
| 10/19/2006 | US20060233813 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| 10/19/2006 | US20060233812 Focussed antibody technology |
| 10/19/2006 | US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/19/2006 | US20060233810 Methods and compositions for treating or preventing cancer |
| 10/19/2006 | US20060233809 Method for treating prostate conditions |
| 10/19/2006 | US20060233808 Peptabody for cancer treatment |
| 10/19/2006 | US20060233807 Novel therapies and methods of screening for therapeutic compounds |
| 10/19/2006 | US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo |
| 10/19/2006 | US20060233805 Antigen uptake receptor for candida albicans on dendritic cells |
| 10/19/2006 | US20060233804 IGF antagonist peptides |
| 10/19/2006 | US20060233803 treating an inflammatory disorder characterized by elevated expression of the polypeptide of SEQ ID NO: 32 in human, comprising administering an immunoadhesin comprising an extracellular domain sequence of the polypeptide; rheumatoid arthritis, pneumonia, chronic asthma, chronic hepatitis, osteoarthritis |
| 10/19/2006 | US20060233802 Tumour necrosis factor binding ligands |
| 10/19/2006 | US20060233801 TGF- beta binding proteins which can be utilized to increase bone mineralization, and thus may be utilized in treating osteopenia, osteoporosis and bone fractures |
| 10/19/2006 | US20060233800 Biological products |
| 10/19/2006 | US20060233799 Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases |
| 10/19/2006 | US20060233798 Methods for inhibiting HIV-1 infection |
| 10/19/2006 | US20060233797 Treatment of inflammatory bowel disease (IBD) |
| 10/19/2006 | US20060233796 Method of modulating memory effector T-cells and compositions |
| 10/19/2006 | US20060233795 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells |
| 10/19/2006 | US20060233794 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 10/19/2006 | US20060233793 Use of anti-cd100 antibodies |
| 10/19/2006 | US20060233792 novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents |
| 10/19/2006 | US20060233791 Anti-CD19 antibodies and uses in oncology |
| 10/19/2006 | US20060233790 Immunoglobulin/hydrophilic peptide complexes |
| 10/19/2006 | US20060233789 Process for producing antigenic substance |
| 10/19/2006 | US20060233788 Anti-ghrelin antibodies |
| 10/19/2006 | US20060233787 Human cd3-specific antibody with immunosuppressive properties |
| 10/19/2006 | US20060233786 Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
| 10/19/2006 | US20060233785 Immunointeractive molecules and uses thereof |
| 10/19/2006 | US20060233781 Antimicrobial composition for local use on mucosal membranes and skin |
| 10/19/2006 | US20060233770 a human cell line, which lacks major histocompatibility class I (MHC-I) and class II (MHC-II) antigens, has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a nucleotide sequence encoding an antigen of Epstein-Barr virus |
| 10/19/2006 | US20060233761 Alkyl-glycoside enhanced vaccination |
| 10/19/2006 | US20060233758 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| 10/19/2006 | US20060233756 Recombinant adenoviral vectors and applications thereof |
| 10/19/2006 | US20060233751 Population of natural cells, 50% are autoantigen-specific regulatory T cells |
| 10/19/2006 | US20060233750 Materials and method of modulating the immune response |
| 10/19/2006 | US20060233712 Magnetic nanoparticles |
| 10/19/2006 | US20060233710 Prevention and treatment for GVHD |
| 10/19/2006 | DE202006001133U1 Multifunctional active agent mixture, useful as auxiliary material in virus vaccine or vaccine to treat cancer, comprises fraction of specific peptide in polypetide chain and fraction with essential and non-essential amino acids |